The high cost of Alzheimer's drugs raises questions about healthcare regulations, costs and price gouging. Medicare Part B, a regulatory body that covers healthcare expenses, is meant to give physicians the knowledge to make informed decisions about the drugs they recommend to patients, but it also rewards them with a 6% kickback of the drug's price, further inflating the cost of drugs.